U.S. Markets closed

Biogen Stock Slips After EU Regulator Has Doubts on Controversial Alzheimer’s Therapy

·2 min read
Biogen Stock Slips After EU Regulator Has Doubts on Controversial Alzheimer’s Therapy
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • BIIB

Biogen says it will continue to engage with the European Medicines Agency and its advisory committee.